Tracon Pharmaceuticals Obtains $14,000,000 New Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=570bc98d-1f60-4b12-9b2a-a7f338a799c5&Preview=1
Date
4/1/2011
Company Name
Tracon Pharmaceuticals
Mailing Address
8910 University Center Dr. San Diego, CA 92122
Company Description
TRACON Pharmaceuticals, Inc. is a fast growing biotechnology company developing next-generation targeted therapies for cancer and related diseases. We are addressing unmet needs in this arena with product candidates that focus on cellular targets specifically implicated in cancer growth and angiogenesis.
Website
http://www.traconpharma.com
Transaction Type
Venture Equity
Transaction Amount
$14,000,000
Transaction Round
Undisclosed
Proceeds Purposes
Proceeds from the financing will advance the development of the antibody TRC105, an inhibitor of angiogenesis that is being developed in multiple Phase 1b and Phase 2 indications, that are supported by the National Cancer Institute, including ongoing trials in prostate, bladder and liver cancer.
M&A Terms
Venture Investor
Jafco Ventures
Venture Investor
Nextech Invest
Venture Investor
Arcus Ventures
Venture Investor
Brookline Venture Partners
Venture Investor
Undisclosed